• News / Press
  • Contact
Arcutis Biotherapeutics Logo
  • Who We Are
    • Vision
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Strategic Collaborations
  • Our Focus
    • Plaque Psoriasis
    • Atopic Dermatitis
    • Eczema
    • Vitiligo
    • Alopecia Areata
    • Seborrheic Dermatitis
  • Pipeline
    • ARQ-151
    • ARQ-154
    • ARQ-252
  • Clinical Trials
  • Investors
Arcutis Biotherapeutics Logo
bubble image

News / Press

ARQ-151 Plaque Psoriasis Program

Posted on May 7, 2019 by ArqAdmin - Press Releases

ARQ-151-Plaque-Psoriasis-Program
Download

Recent Posts

  • Arcutis Announces ARQ-154 Program for Seborrheic Dermatitis and Enrollment of First Patient in Phase 2 Proof of Concept Clinical Trial
  • Arcutis Appoints Keith Klein as General Counsel
  • Arcutis Announces Addition of Three Senior Biopharmaceutical Executives to Management Team
  • Arcutis Biotherapeutics Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Phase 3 Program for ARQ-151 for Plaque Psoriasis
  • Arcutis Announces the Completion of $94.5 million Series C Financing

Archives

  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019

Categories

  • Press Releases
Arcutis Biotherapeutics Logo
805.418.5006
information@arcutis.com
  • linkedin
  • Who We Are
  • Our Focus
  • Pipeline
  • Clinical Trials
  • Investors
  • Contact
  • News / Press
  • Legal Disclaimer

© 2019 Arcutis Biotherapeutics

Designed By Watermark